“We have been developing the technology for a number of years and have, with partners, worked on more than 50 projects developing high-yield Chinese hamster ovary (CHO) cell lines expressing ...

tebu-bio offers recombinant protein production services using a robust, inexpensive and fast transient-expression system in Chinese hamster ovary (CHO) cells, for various research and development ...

ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002.

ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...

Lotte Biologics announced on the 13th that it has signed a memorandum of understanding (MOU) for collaboration in the ...

U.S. cellular starting materials Market Size was valued at USD 0.68 Billion in 2024 and is expected to reach USD 4.45 Billion by 2034 growing at a CAGR of 20.4%.